Poniard Pharmaceuticals, Inc.
PARDOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$150
P/E Ratio—
52W High$0.0001
52W Low$0.00001
Poniard Pharmaceuticals, Inc. (PARD) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PARD · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2010-12 | 2009-12 | 2008-12 | 2007-12 | 2006-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.03B | $0.03B | $0.02B | $0.01B |
| G&A Expenses | $0.02B | $0.01B | $0.01B | $0.00B | $0.00B |
| Total Operating Expenses | $0.03B | $0.04B | $0.05B | $0.04B | $0.02B |
| Operating Income | ($0.03B) | ($0.04B) | ($0.05B) | ($0.04B) | ($0.02B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.03B) | ($0.05B) | ($0.05B) | ($0.03B) | ($0.02B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-26.40 | $-52.40 | $-56.40 | $-43.20 | $-54.80 |
| Wtd Avg Shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.03B) | ($0.04B) | ($0.05B) | ($0.03B) | ($0.02B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Poniard Pharmaceuticals, Inc. data
About Poniard Pharmaceuticals, Inc. (PARD) Income Statement
Poniard Pharmaceuticals, Inc. (PARD) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2010, PARD reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.03B) — a net profit margin of —.
Frequently asked questions
PARD · 4 questionsPoniard Pharmaceuticals, Inc. (PARD) reported revenue of $0.00B for 2010, down —% year-over-year.
PARD revenuePARD salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09